Celogics

Celogics is a biotechnology startup founded in 2021 with the slogan "Offering High-quality iPSC-derived Cell Products for Disease Modeling, Drug Discovery, and Drug Safety Screening." The company's mission is to revolutionize human cell culture and research by becoming the leading manufacturer of iPSC-derived cells for various applications. Recognizing the limitations of traditional research methods in Life Sciences and Pharmaceutical research, Celogics aims to introduce next-generation human cell models to the industry.

Celogics is committed to producing top-tier human cells that not only meet the standards of iPSC-derived cells but also excel as the best functional cells for research purposes. The company prioritizes users' needs and strives to deliver high-quality cells, positioning its initial product offering, Celo.Cells, as research-use-only iPSC-derived cell products for drug discovery, drug safety screening, and disease modeling.

As a newly formed joint venture between Curi Bio (www.curibio.com) and NEXEL (www.nexel.co.kr), Celogics is in the process of building a 22,000 square feet facility in the United States. The startup presents an opportunity for potential investors to participate in this compelling venture, as it aspires to innovate the field of biotechnology and manufacturing.

Currently, there is no available information regarding Celogics' last investment or associated investors.